INFI
$0.98
Infinity Pharmaceuti
($.02)
(1.99%)
INFI
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.15)
Revenue:  N/A
Thursday
Oct 29
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when INFI reports earnings?
Beat
Meet
Miss

Where is INFI's stock price going from here?
Up
Flat
Down
Stock chart of INFI
Analysts
Summary of analysts' recommendations for INFI
Score
Grade
Pivots
Resistance
$1.03
$1.01
$1.00

$0.98

Support
$0.96
$0.94
$0.93
Tweet
Growth
Description
Infinity Pharmaceuticals, Inc. is an innovative cancer drug discovery and development company that is seeking to leverage its strength in small molecule drug technologies to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions.
Peers
InterCeptRegeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalJohnson & JohnsonZoetisBristol-Myers SquibbUltragenyx PharmaceuticalCatalentMerck & Co.